Cardiovascular Medicine webinar — Reperfusion therapy for STEMI: A case for the pharmacoinvasive approach even in the USA March 12, 2021 Overview Show transcript Overview In this Cardiovascular Medicine webinar, Reperfusion therapy for ST-elevated myocardial infarction (STEMI): A case for the pharmacoinvasive approach even in the USA, Mayo Clinic cardiology experts Bernard J. Gersh, M.B., Ch.B., D.Phil., and Mandeep Singh, M.D., focus on the impact of early reperfusion on infarct size and outcomes with an emphasis on a systems approach in communities that do not have a percutaneous coronary intervention (PCI)-capable catheterization laboratory and consequently rely on rapid transport to a referral hospital with the requisite facilities. The advantages and disadvantages of thrombolysis followed by transport (the "drip and ship" or pharmacoinvasive approach) are discussed, as are barriers to optimizing this therapeutic strategy. For more information or to refer a patient, visit Mayo Clinic Medical Professionals — Cardiovascular Diseases. Share Doximity Facebook LinkedIn Twitter Print details Receive Mayo Clinic news in your inbox. Sign up Related ContentVideoLessons from China on critical care considerations and staff safety during COVID-19 Q and AA patient with traumatic injury has had an MI: What's next for the patient's care? VID-20525164 Medical Professionals Cardiovascular Medicine webinar — Reperfusion therapy for STEMI: A case for the pharmacoinvasive approach even in the USA